9 July 2020
• RECCE® 327 and New RECCE® 529 compounds were selected for their unique mechanism of actions against hyper-mutation, as indicated on bacteria and viruses (respectively)
• Testing program will be conducted by CSIRO & University of Melbourne at the Doherty Institute
• Therapeutic antiviral treatment focus of RECCE® 327 and RECCE® 529 may see added potential benefit against secondary bacterial infections
Recce Pharmaceuticals Ltd, the Company developing New Classes of Synthetic Anti-infectives, today announced it has entered into an Antiviral SARS-CoV-2 Screening Program Agreement, with The Commonwealth Scientific and Industrial Research Organisation (CSIRO) and the University of Melbourne at The Peter Doherty Institute for Infection and Immunology (‘Doherty Institute’) following their selection of RECCE® 327 and RECCE® 529’s in the Priority 1 candidate group.
According to the Program Selection Guidelines, Priority 1 status is defined as “highest or strong likelihood of antiviral or antiseptic efficacy – Compounds in this grouping will be eligible for stage 1 laboratory screening trials”. RECCE® 327 is a broad-spectrum synthetic antibiotic formulated using synthetic polymer technology to treat blood infections and sepsis. RECCE® 529 is a new synthetic polymer formulation, built upon the Company’s anti-infective expertise.
Submissions were assessed by a panel of scientific experts in virology, antivirals, medicinal chemistry and the clinical trial of antiviral drugs. The SARS-CoV-2 Antiviral Screening Program evaluating the Company’s compounds is a three step process involving (1) In-vitro screening/testing, (2) Ex-vivo testing using a model of human epithelial lung cells at Doherty Institute and (3) In-vivo (ferrets) in CSIRO’s Australian Centre for Disease Preparedness.
The Program is part of the Australian Government’s efforts to identify promising anti-viral candidates and fast-track research into potential treatments for COVID-19.
Read the full media release from Recce Pharmaceuticals here.